secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amylyx Pharmaceuticals, Inc. (AMLX)
CIK:        0001658551
Form:       8-K
Filed at:   2023-07-26T23:59:59+00:00
Accession:  0001193125-23-194655
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amylyx announces conference call on AMX0035 Phase 3 PSP trial; no new data
--------------------------------------------------------------------------

- Hosted investor call on July 26, 2023 to discuss PSP and Orion Phase 3 trial of AMX0035.
- No clinical results or data disclosed; only trial design and scientific rationale overview.
- Presenters included co-CEOs, clinical development head, and external investigator Prof. Höglinger.
- Attached slides outline rationale and design, not outcomes or milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658551/000119312523194655/0001193125-23-194655-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658551/000119312523194655/d498667d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-194655

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer